已收盘 12-19 16:00:00 美东时间
-0.020
-0.87%
Connect Biopharma Holdings Limited will present two studies on rademikibart, an anti-IL-4Rα antibody, at the EAACI 2025 Annual Congress in Glasgow. The presentations focus on reducing asthma exacerbations and improving lung function in eosinophilic-driven, Type 2 asthma. Rademikibart has shown promising results in Phase 2 trials, including rapid improvement in FEV1.
06-03 13:00
Connect Biopharma Holdings Limited announced that its management will participate in the Noble Capital Markets Virtual Conference on June 4, 2025, and the Jefferies Healthcare Conference on June 5, 2025. The company, focused on developing treatments for asthma and COPD, is advancing rademikibart, a next-generation antibody showing strong efficacy and safety in Phase 2 trials.
05-28 13:00
北京时间2025年02月04日03时33分,康乃德生物(CNTB.us)股票出现异动,股价快速拉升7.00%。截至发稿,该股报1.040美元/股,成交量2.2915万股,换手率0.04%,振幅7.20%。 最近的财报数据显示,该股实现营业收入24.12百万美元,净利润7.65百万美元,每股收益0.14美元,毛利23.64百万美元,市盈率-2.67倍。 机构评级方面,在所有1家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。 康乃德生物股票所在的生物技术行业中,整体跌幅为0.21%。其相关个股中,Hcw Biologics Inc.、Invivyd, Inc.、Gh Re...
02-04 03:33
北京时间2025年01月18日03时00分,康乃德生物(CNTB.us)股票出现异动,股价急速拉升5.36%。截至发稿,该股报1.10美元/股,成交量5804股,换手率0.01%,振幅6.70%。 最近的财报数据显示,该股实现营业收入24.12百万美元,净利润7.65百万美元,每股收益0.14美元,毛利23.64百万美元,市盈率-2.79倍。 机构评级方面,在所有1家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。 康乃德生物股票所在的生物技术行业中,整体涨幅为0.62%。其相关个股中,Channel Therapeutics Corporation、Silexion ...
01-18 03:00
北京时间2024年10月05日02时36分,康乃德生物(CNTB.us)股票出现波动,股价快速下跌5.11%。截至发稿,该股报1.39美元/股,成交量3.6535万股,换手率0.07%,振幅8.87%。 最近的财报数据显示,该股实现营业收入24.12百万美元,净利润7.65百万美元,每股收益0.14美元,毛利23.64百万美元,市盈率-3.62倍。 机构评级方面,在所有1家参与评级的机构中,100%的券商给予买入建议,无券商给予持有、卖出建议。 康乃德生物股票所在的生物技术行业中,整体跌幅为0.24%。其相关个股中,Lexaria Bioscience Corp C/Wts 14/01/202...
2024-10-05 02:36
HC Wainwright & Co. analyst Emily Bodnar reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $8 price target.
2024-09-06 19:33
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly earnings of $0.14 per share. This is a 125.45 percent increase over losses of $(0.55) per share from the same period last year. The company reported $24.12
2024-09-06 04:35